Goldfinch Bio Inc. CEO Anthony Johnson told BioWorld that his company's deal with Gilead Sciences Inc. represents "a phenomenal opportunity, because this [kidney disease patient registry] will be the biggest of its type, definitely for the kidney but arguably across other disease areas as well."